Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Clinical trial NCT05248659 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05248659
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-05
- Primary completion
- 2028-12-28
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.